Premium
Elevated serum progastrin‐releasing peptide (31–98) in metastatic and androgen‐independent prostate cancer patients *
Author(s) -
Yashi Masahiro,
Muraishi Osamu,
Kobayashi Yutaka,
Tokue Akihiko,
Nanjo Hiroshi
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10063
Subject(s) - chromogranin a , prostate cancer , medicine , prostate , androgen , gastrin releasing peptide , immunohistochemistry , hyperplasia , cancer , endocrinology , hormone , bombesin , neuropeptide , receptor
BACKGROUND Increases in neuroendocrine phenotype and secretory products are closely correlated with tumor progression and androgen independence in prostate cancer. In this study, we explored this correlation using serum progastrin‐releasing peptide (ProGRP), a carboxy‐terminal region common to three subtypes of precursors for gastrin‐releasing peptide (GRP), which is released from the neuroendocrine phenotype to act as a growth factor. METHODS In 60 patients with benign prostatic hyperplasia (BPH) and 200 with prostate cancer, serum ProGRP levels were determined with an enzyme‐linked immunosorbent assay (ELISA) kit and evaluated in relation to clinical stage, hormonal treatment, and prostate‐specific antigen (PSA) values. Fourteen randomly selected patients were entered in the follow‐up study. Additionally, expression of ProGRP as determined by immunohistochemical analysis was compared to that of chromogranin‐A (CgA) in tissue samples from several subjects. RESULTS We found a positive correlation between PSA and ProGRP in patients with untreated prostate cancer; no correlation was found in the treated groups. The increases in the ProGRP value and in the percentage of patients with higher than normal values were significant ( P < 0.0001), especially in the androgen‐independent group ( P < 0.0001). A longitudinal study showed that, in a subset of patients, the ProGRP values tended to increase transiently when the cancer became androgen independent, but remained unchanged or decreased at the androgen‐dependent stage. Positive staining for ProGRP occurred in a different distribution in neuroendocrine tissues than that of staining for CgA. CONCLUSIONS The clinical results demonstrated the existence of a regulatory mechanism for GRP, which to date had only been observed in cell lines. These findings suggest that GRP is a growth factor potentially upregulated by androgen but that does not rely principally on androgen modulation. The large overlap in levels of ProGRP among the groups limits the use of this value as a monitoring tool. Measurement of ProGRP, however, does have potential as an independent parameter to evaluate androgen‐independent progression and to facilitate a new therapeutic strategy that may compensate for current limitations of diagnosis based on PSA alone. Prostate 51: 84–97, 2002. © 2002 Wiley‐Liss, Inc.